mRNA-2808 / Moderna - LARVOL DELTA

A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma. (ASCO 2026) - P1/2 | "Additional exploratory endpoints will evaluate surrogates of efficacy, mechanism of action, and characterize exposure. Dose Levels 1 and 2 have been completed without DLT and dose escalation is ongoing (NCT07116616)."

First-in-human • P1/2 data • Hematological Malignancies • Multiple Myeloma • Plasmacytoma

Moderna Science Day Highlights Expanding Potential of mRNA Platform (Investing News Network (INN)) - "Early Pipeline Progress: The Phase 1 study is ongoing with mRNA-4106 as monotherapy in advanced solid tumors...mRNA-4359 (Cancer antigen therapy): Designed to elicit T-cell immune responses against tumor and immunosuppressive cells, the Phase 1/2 study is ongoing with the Phase 2 portion including cohorts in first-line metastatic melanoma and first-line metastatic non-small cell lung cancer (NSCLC)....mRNA-2808 (T-cell engager): Designed to use multiplexed T-cell engagers to improve efficacy and overcome mechanisms of resistance for multiple myeloma, the Phase 1/2 study is ongoing and includes three distinct T-cell engagers against clinically validated targets....mRNA-2151 (T-cell engager)....this preclinical multiplexed T-cell engager program is moving toward early development in ovarian cancer."

Preclinical • Trial status • Melanoma • Multiple Myeloma • Non Small Cell Lung Cancer • Ovarian Cancer • Solid Tumor

Moderna, Inc…announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants with relapsed or refractory multiple myeloma (RRMM). (ACCESS Newswire)

Trial status • Multiple Myeloma

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=166 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=166 | Not yet recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology